Citations

Showing 10 of 108119 citations.

Author Reply
Crippa, Jacopo , Larson, David W.

Mayo Clinic

Diseases of the Colon & Rectum | October 13, 2021 | Volume: 66 | Issue: 4 | Pages: e177-e177

10.1097/dcr.0000000000002309 | PMID 34636784 Get It

Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic
Alwan, Laura, Bachiashvili, Kimo, Cool, Rita, Curtin, Peter , Gojo, Ivana , Kidwai, Wajih Zaheer, Kloth, Dwight D. , Kraut, Eric H., Perez, Lia, Rosovsky, Rachel , Vasu, Sumithira , Wadleigh, Martha , Westervelt, Peter, Griffiths, Elizabeth A. , Brown, Anna Mary , Geyer, Mark Blaine , Kallam, Avyakta , Lyman, Gary H , Mukherjee, Sudipto , Roy, Vivek , Rugo, Hope S. , Becker, Pamela S.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 13, 2021 | Volume: 19 | Issue: 13 | Pages: 18-21

10.6004/jnccn.2020.7610 | PMID 32871558 Get It

Hematopoietic growth factors, including erythrocyte stimulating agents (ESAs), granulocyte colony-stimulating factors, and thrombopoietin mimetics, can mitigate anemia, neutropenia, and thrombocytopenia resulting from chemotherapy for the treatment of cancer. In the context of pandemic SARS-CoV-2 infection, patients with cancer have been identified as a group at high risk of morbidity and mortality from this infection. Our subcommittee of the NCCN Hematopoietic Growth Factors Panel convened a voluntary group to review the potential value of expanded use of such growth factors in the current high-risk environment. Although recommendations are available on the NCCN website in the COVID-19 Resources Section (https://www.nccn.org/covid-19/), these suggestions are provided without substantial context or reference. Herein we review the rationale and data underlying the suggested alterations to the use of hematopoietic growth factors for patients with cancer in the COVID-19 era.
Lymphedema Is a Significant Risk Factor for Failure After Primary Total Hip Arthroplasty
Rainer, W. Gerald , Kolz, Joshua M. , Wyles, Cody C. , Houdek, Matthew T. , Perry, Kevin I. , Lewallen, David G. , Rainer, William G , Houdek, Matthew T , Wyles, Cody C

Mayo Clinic

Journal of Bone and Joint Surgery | October 13, 2021 | Volume: 104 | Issue: 1 | Pages: 55-61

10.2106/jbjs.20.01970 | PMID 34637411 Get It

Background: Lymphedema is a chronic disease characterized by fluid buildup and swelling that can lead to skin and soft-tissue fibrosis and recurring soft-tissue infections. Literature with regard to the increased risk of complications following a surgical procedure in patients with lymphedema is emerging, but the impact of lymphedema in the setting of primary total hip arthroplasty (THA) remains unknown. The purpose of this study was to review outcomes following primary THA performed in patients with lymphedema compared with a matched cohort without lymphedema. Methods: Using our institutional total joint registry and medical records, we identified 83 patients (57 were female and 26 were male) who underwent THA with ipsilateral lymphedema. For comparison, these patients were matched 1:6 (based on sex, age, date of the surgical procedure, and body mass index [BMI]) to a group of 498 patients without lymphedema who underwent primary THA for osteoarthritis. Subsequently, postoperative complications and implant survivorship were evaluated for each group. The mean follow-up for each group was 6 years. Survivorship was compared between cohorts using Kaplan-Meier methodology and included both survivorship free of infection and survivorship free of reoperation or revision. Univariate Cox regression analysis was utilized to assess the association between patient factors for the time to event outcomes noted above. Results: In patients with a history of lymphedema, there was an increased risk of complications (hazard ratio [HR], 1.97; p < 0.01), including reoperation for any cause (HR, 3.16; p < 0.01) and postoperative infection (HR, 4.48; p < 0.01). The 5-year infection-free survival rate was 90.3% for patients with lymphedema compared with 97.7% for patients without lymphedema (p < 0.01). Conclusions: Patients with lymphedema are at increased risk for complications, including reoperation and infection, following primary THA. These data emphasize the importance of appropriate preoperative counseling in this population and should encourage efforts to identify methods to improve outcomes, including further investigation of the effects of preoperative optimization of lymphedema prior to THA and methods for improved perioperative management. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
T2* reduction in patients with acute post-traumatic headache
Nikolova, Simona , Li, Jing , Dumkrieger, Gina , Ross, Katherine , Chong, Catherine D. , Dumkrieger, Gina , Chong, Catherine D , Schwedt, Todd J. , Wu, Teresa , Berisha, Visar

Mayo Clinic

Cephalalgia | October 13, 2021 | Volume: 42 | Issue: 4-5 | Pages: 357-365

10.1177/03331024211048509 | PMID 34644192 Get It

Objectives Although iron accumulation in pain-processing brain regions has been associated with repeated migraine attacks, brain structural changes associated with post-traumatic headache have yet to be elucidated. To determine whether iron accumulation is associated with acute post-traumatic headache, magnetic resonance transverse relaxation rates (T2*) associated with iron accumulation were investigated between individuals with acute post-traumatic headache attributed to mild traumatic brain injury and healthy controls. Methods Twenty individuals with acute post-traumatic headache and 20 age-matched healthy controls underwent 3T brain magnetic resonance imaging including quantitative T2* maps. T2* differences between individuals with post-traumatic headache versus healthy controls were compared using age-matched paired t-tests. Associations of T2* values with headache frequency and number of mild traumatic brain injuries were investigated using multiple linear regression in individuals with post-traumatic headache. Significance was determined using uncorrected p-value and cluster size threshold. Results Individuals with post-traumatic headache had lower T2* values compared to healthy controls in cortical (bilateral frontal, bilateral anterior and posterior cingulate, right postcentral, bilateral temporal, right supramarginal, right rolandic, left insula, left occipital, right parahippocampal), subcortical (left putamen, bilateral hippocampal) and brainstem regions (pons). Within post-traumatic headache subjects, multiple linear regression showed a negative association between T2* in the right inferior parietal/supramarginal regions and number of mild traumatic brain injuries and a negative association between T2* in bilateral cingulate, bilateral precuneus, bilateral supplementary motor areas, bilateral insula, right middle temporal and right lingual areas and headache frequency. Conclusions Acute post-traumatic headache is associated with iron accumulation in multiple brain regions. Correlations with headache frequency and number of lifetime mild traumatic brain injuries suggest that iron accumulation is part of the pathophysiology or a marker of mild traumatic brain injury and post-traumatic headache.
­TREM2-H157Y Increases Soluble TREM2 Production and Reduces Amyloid Pathology
Qiao, Wenhui , Chen, Yixing , Martens, Yuka A. , Li, Fuyao , Aishe, Kurti I., Dacquel, Maxwell V., Fryer, John Denis , Chen, Kai , Li, Fuyao , Liu, Chia‐Chen , Knight, Joshua A. , Chen, Kai , Shue, Francis , Zhao, Na , Bu, Guojun

Mayo Clinic

No container title available | October 13, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-960300/v1 Get It

Abstract Background: The p.H157Y variant of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) has been reported to increase Alzheimer’s disease (AD) risk. This mutation in the extracellular domain of TREM2 localizes at the cleavage site and was shown to enhance shedding and impair phagocytosis in vitro by ectopic expression of TREM2-H157Y in HEK293 cells. However, the physiological and AD-related outcomes of TREM2 H157Y mutation in vivo remain unknown.Methods: We generated a novel Trem2 H157Y knock-in mouse model through CRISPR-Cas9 technology and investigated how Trem2 H157Y mutation impacts TREM2 proteolytic processing, synaptic function, and AD-related amyloid pathology by conducting biochemical assays, immunofluorescent staining, hippocampal electrophysiology, and in vivo micro-dialysis in awake, free-moving animals.Results: Consistent with previous in vitro findings, TREM2-H157Y increases the amount of soluble TREM2 (sTREM2) in the cortex and serum of mutant mice compared to the wild type controls. Interestingly, the Trem2 H157Y variant enhances synaptic plasticity without affecting microglial density and morphology. In the presence of amyloid pathology, TREM2-H157Y surprisingly accelerates Aβ clearance and reduces amyloid burden and microgliosis. Conclusion: Taken together, our findings support a beneficial effect of the Trem2 H157Y mutation in synaptic function and in mitigating amyloid pathology. Considering the genetic association of TREM2 p.H157Y with AD, we speculate TREM2-H157Y might increase AD risk through an amyloid-independent pathway, as such its effects on tauopathy and neurodegeneration merit further investigation.
Proceedings of the 43nd Annual Upper Midwest Neuro-Ophthalmology Group Meeting, July 23, 2021 and Second Virtual Upper Midwest Neuro-Ophthalmology Group Meeting
Tajfirouz, Deena , Judge, Casey, Chen, John J. , Chen, John J , McClelland, Collin M.

Mayo Clinic

Neuro-Ophthalmology | October 13, 2021 | Volume: 45 | Issue: 6 | Pages: 411-416

10.1080/01658107.2021.1981948 | PMID 34720274 Get It

Trends in Electronic Health Record Inbox Messaging During the COVID-19 Pandemic in an Ambulatory Practice Network in New England
Nath, Bidisha , Williams, Brian , Jeffery, Molly M. , O’Connell, Ryan , Goldstein, Richard , Sinsky, Christine A. , Melnick, Edward R. , Jeffery, Molly Moore , Melnick, Edward R

Mayo Clinic

JAMA Network Open | October 13, 2021 | Volume: 4 | Issue: 10 | Pages: e2131490

10.1001/jamanetworkopen.2021.31490 | PMID 34636917 Get It

Metabolic responsiveness to training depends on insulin sensitivity and protein content of exosomes in insulin-resistant males
Apostolopoulou, Maria , Mastrototaro, Lucia , Hartwig, Sonja , Pesta, Dominik , Straßburger, Klaus , Filippo, Elisabetta De, Jeleník, Tomáš , Karusheva, Yanislava , Gancheva, Sofiya , Markgraf, Daniel F. , Herder, Christian , Lehr, Stefan , Müssig, Karsten , Al‐Hasani, Hadi , Szendroedi, Julia, Markgraf, Daniel , Nair, K Sreekumaran , Reichert, Andreas S , Lehr, Stefan , Szendroedi, Julia , Roden, Michael , Nair, K. Sreekumaran

Mayo Clinic

Science Advances | October 13, 2021 | Volume: 7 | Issue: 41 | Pages: No page available

10.1126/sciadv.abi9551 | PMID 34623918 Get It

SEV may serve as new biomarkers for predicting the individual response of insulin sensitivity to exercising.
Embotrap Extraction & Clot Evaluation & Lesion Evaluation for NeuroThrombectomy (EXCELLENT) Registry design and methods
Siddiqui, Adnan H. , Waqas, Muhammad , Brinjikji, Waleed , Doyle, Karen , Fiehler, Jens , Hacke, Werner , Hanel, Ricardó A. , Liebeskind, David S. , Zaidat, Osama O. , Doyle, Karen M , Fiehler, Jens , Hanel, Ricardo A , Zaidat, Osama O , Liebeskind, David S. , Waqas, Muhammad , Siddiqui, Adnan H , De Meyer, Simon F , Jovin, Tudor G. , Yoo, Albert J. , Andersson, Tommy , Nogueira, Raul G.

Mayo Clinic

Journal of NeuroInterventional Surgery | October 13, 2021 | Volume: 14 | Issue: 8 | Pages: 783-787

10.1136/neurintsurg-2021-017671 | PMID 34645704 Get It

Background Relationships between occlusive clot histopathology, baseline characteristics, imaging findings, revascularization rates, and clinical outcomes of stroke patients with large vessel occlusion (LVO) are not well understood. This study will assess the real-world experience on the efficacy and safety of using the EmboTrap device as the first approach in LVO patients and explore the associations between clot histological characteristics, imaging and clinical findings, revascularization rates, and clinical outcomes. Methods Prospective, global, multicenter, single-arm, imaging core laboratory, and clot analysis central laboratory observational registry. Adult patients (>18 years) with LVO, treated with EmboTrap as the first attempted device, will be eligible for study participation. Results Up to 1000 subjects at 50 international sites may be enrolled. Occlusive clots will be collected from at least 500 subjects. Independent central and imaging core laboratories will perform clot analysis and image adjudication. Statistical analysis will assess the association between imaging and clinical findings, clot characteristics, subject comorbidities, revascularization, and clinical outcomes. Study endpoints are functional independence (modified Rankin Scale score ≤2 at 90 days), expanded Thrombolysis In Cerebral Infarction (eTICI) score ≥2b50 rate, first-pass effect, number of passes, embolization into new territory, symptomatic intracranial hemorrhage, and 90-day mortality. Conclusions The EXCELLENT registry will provide reproducible effectiveness and safety data of EmboTrap for its use for mechanical thrombectomy. Additionally, the study will characterize the blood clots retrieved during mechanical thrombectomy with respect to their composition and histopathological analysis and potential correlations with clinical and imaging findings. Trial registration number NCT03685578 .
Longitudinal associations between family conflict, parent engagement, and metabolic control in children with recent-onset type 1 diabetes
Case, Hannah F., Majidi, Shideh , Ferro, Diana , Patton, Susana R. , Case, Hannah , Williams, David D. , Clements, Mark A

Mayo Clinic

BMJ Open Diabetes Research & Care | October 13, 2021 | Volume: 9 | Issue: 1 | Pages: e002461

10.1136/bmjdrc-2021-002461 | PMID 34645616 Get It

Introduction We prospectively investigated the associations between diabetes-related family conflict, parent engagement in child type 1 diabetes (T1D) care, and child glycated hemoglobin (HbA1c) in 127 families of school-age children who we recruited within the first year of their T1D diagnosis. Research design and methods Parents completed the Diabetes Family Conflict Scale-Revised (DFCS-R) to assess for diabetes-related family conflict and the Diabetes Self-Management Questionnaire-Brief (DSMQ-Brief) to assess parent engagement in child T1D care at the initial study visit (T1) and at 12 (T2) and 27 (T3) months later. We also collected child HbA1c at these time points. Our analyses included Pearson correlations and repeated measures linear mixed models controlling for child age, sex, and T1D duration at T1. Results Parents’ DFCS-R scores negatively correlated with DSMQ-Brief scores (r=−0.13, p<0.05) and positively correlated with children’s HbA1c (r=0.26, p<0.001). In our linear mixed models, parents’ DSMQ-Brief scores were unchanged at T2 (β=−0.71, 95% CI −1.59 to 0.16) and higher at T3 (β=8.01, 95% CI 6.89 to 9.13) compared with T1, and there was an association between increasing DFCS-R and decreasing DSMQ-Brief scores (β=−0.14, 95% CI −0.21 to −0.06). Child HbA1c values were significantly higher at T2 (β=0.66, 95% CI 0.38 to 0.94) and T3 (β=0.95, 95% CI 0.63 to 1.27) compared with T1, and there was an association between increasing DFCS-R scores and increasing child HbA1c (β=0.04, 95% CI 0.02 to 0.06). Conclusions Increasing diabetes-specific family conflict early in T1D may associate with decreasing parent engagement in child T1D care and increasing child HbA1c, suggesting a need to assess and intervene on diabetes-specific family conflict. Trial registration number NCT03698708.